Prospects for mucosal vaccine : shutting the door on SARS-CoV-2
The sudden emergence of a highly transmissible and pathogenic coronavirus SARS-CoV-2 in December 2019 from China and its rapid global spread has posed an international health emergency. The rapid development of an effective vaccine is imperative to control the spread of SARS-CoV-2. A number of concurrent efforts to find an effective therapeutic agent or vaccine for COVID-19 (coronavirus disease 2019) are being undertaken globally. Oral and nasal mucosal surfaces serve as the primary portal of entry for pathogens like coronaviruses in the human body. As evidenced by studies on similar coronaviruses (SARS-CoV and MERS-CoV), mucosal vaccination can provide a safe and effective means for the induction of long-lasting systemic and mucosal immunity to confer protection against SARS-CoV-2. This article summarizes the approaches to an effective mucosal vaccine formulation which can be a rewarding approach to combat the unprecedented threat posed by this emerging global pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Human vaccines & immunotherapeutics - 16(2020), 12 vom: 01. Dez., Seite 2921-2931 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mudgal, Rajat [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 15.01.2021 Date Revised 08.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/21645515.2020.1805992 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315032936 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315032936 | ||
| 003 | DE-627 | ||
| 005 | 20231226201911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/21645515.2020.1805992 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315032936 | ||
| 035 | |a (NLM)32931361 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mudgal, Rajat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prospects for mucosal vaccine |b shutting the door on SARS-CoV-2 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2021 | ||
| 500 | |a Date Revised 08.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The sudden emergence of a highly transmissible and pathogenic coronavirus SARS-CoV-2 in December 2019 from China and its rapid global spread has posed an international health emergency. The rapid development of an effective vaccine is imperative to control the spread of SARS-CoV-2. A number of concurrent efforts to find an effective therapeutic agent or vaccine for COVID-19 (coronavirus disease 2019) are being undertaken globally. Oral and nasal mucosal surfaces serve as the primary portal of entry for pathogens like coronaviruses in the human body. As evidenced by studies on similar coronaviruses (SARS-CoV and MERS-CoV), mucosal vaccination can provide a safe and effective means for the induction of long-lasting systemic and mucosal immunity to confer protection against SARS-CoV-2. This article summarizes the approaches to an effective mucosal vaccine formulation which can be a rewarding approach to combat the unprecedented threat posed by this emerging global pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a mucosal vaccine | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Nehul, Sanketkumar |e verfasserin |4 aut | |
| 700 | 1 | |a Tomar, Shailly |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human vaccines & immunotherapeutics |d 2012 |g 16(2020), 12 vom: 01. Dez., Seite 2921-2931 |w (DE-627)NLM21576823X |x 2164-554X |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2020 |g number:12 |g day:01 |g month:12 |g pages:2921-2931 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/21645515.2020.1805992 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2020 |e 12 |b 01 |c 12 |h 2921-2931 | ||